Standard
Response to Pham et al., "More data are needed to confirm the utility of screening for atypical fibroxanthoma and pleomorphic dermal sarcoma recurrence". / Ørholt, Mathias; Eriksson, Frank; Herly, Mikkel; Vester-Glowinski, Peter.
In:
Journal of the American Academy of Dermatology, Vol. 90, No. 5, 2024, p. e175-e176.
Research output: Contribution to journal › Comment/debate › Research › peer-review
Harvard
Ørholt, M
, Eriksson, F, Herly, M & Vester-Glowinski, P 2024, '
Response to Pham et al., "More data are needed to confirm the utility of screening for atypical fibroxanthoma and pleomorphic dermal sarcoma recurrence"',
Journal of the American Academy of Dermatology, vol. 90, no. 5, pp. e175-e176.
https://doi.org/10.1016/j.jaad.2023.12.042APA
Ørholt, M.
, Eriksson, F., Herly, M., & Vester-Glowinski, P. (2024).
Response to Pham et al., "More data are needed to confirm the utility of screening for atypical fibroxanthoma and pleomorphic dermal sarcoma recurrence".
Journal of the American Academy of Dermatology,
90(5), e175-e176.
https://doi.org/10.1016/j.jaad.2023.12.042Vancouver
Ørholt M
, Eriksson F, Herly M, Vester-Glowinski P.
Response to Pham et al., "More data are needed to confirm the utility of screening for atypical fibroxanthoma and pleomorphic dermal sarcoma recurrence".
Journal of the American Academy of Dermatology. 2024;90(5):e175-e176.
https://doi.org/10.1016/j.jaad.2023.12.042Author
Ørholt, Mathias ; Eriksson, Frank ; Herly, Mikkel ; Vester-Glowinski, Peter. / Response to Pham et al., "More data are needed to confirm the utility of screening for atypical fibroxanthoma and pleomorphic dermal sarcoma recurrence". In: Journal of the American Academy of Dermatology. 2024 ; Vol. 90, No. 5. pp. e175-e176.
Bibtex
@article{dfa3b4e92e0d4dcb93651f762429bbd4,
title = "Response to Pham et al., {"}More data are needed to confirm the utility of screening for atypical fibroxanthoma and pleomorphic dermal sarcoma recurrence{"}",
abstract = "To the Editor: We thank Pham et al1 for their interest in our study on patients with atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS),2 and we appreciate the opportunity to discuss and clarify our analysis further.",
author = "Mathias {\O}rholt and Frank Eriksson and Mikkel Herly and Peter Vester-Glowinski",
year = "2024",
doi = "10.1016/j.jaad.2023.12.042",
language = "English",
volume = "90",
pages = "e175--e176",
journal = "American Academy of Dermatology. Journal",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "5",
}
RIS
TY - JOUR
T1 - Response to Pham et al., "More data are needed to confirm the utility of screening for atypical fibroxanthoma and pleomorphic dermal sarcoma recurrence"
AU - Ørholt, Mathias
AU - Eriksson, Frank
AU - Herly, Mikkel
AU - Vester-Glowinski, Peter
PY - 2024
Y1 - 2024
N2 - To the Editor: We thank Pham et al1 for their interest in our study on patients with atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS),2 and we appreciate the opportunity to discuss and clarify our analysis further.
AB - To the Editor: We thank Pham et al1 for their interest in our study on patients with atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS),2 and we appreciate the opportunity to discuss and clarify our analysis further.
U2 - 10.1016/j.jaad.2023.12.042
DO - 10.1016/j.jaad.2023.12.042
M3 - Comment/debate
C2 - 38185254
VL - 90
SP - e175-e176
JO - American Academy of Dermatology. Journal
JF - American Academy of Dermatology. Journal
SN - 0190-9622
IS - 5
ER -
